Best Peptide for Long COVID

Long COVID is a multi-system syndrome driven by mitochondrial dysfunction, gut permeability, neuroinflammation, residual viral persistence, pulmonary fibrosis, and immune dysregulation. Peptide therapies targeting each of these pathologies — BPC-157, LL-37, TB-500, VIP, and thymosin alpha-1 — are among the most actively explored treatments outside of conventional medicine for post-COVID syndrome recovery.

There is no single best peptide for long COVID because it is a multi-system condition. The most commonly used combination targets: BPC-157 (mitochondrial dysfunction, gut permeability, MCAS), LL-37 (residual viral persistence), TB-500 (pulmonary fibrosis, lung tissue repair), VIP intranasal (neuroinflammation, brain fog), and Thymosin Alpha-1 (immune reconstitution).

Most long COVID peptide protocols use 2–4 of these in combination.

BPC-157 addresses two major long COVID fatigue mechanisms: mitochondrial dysfunction (via SIRT1 activation and oxidative stress reduction) and gut barrier disruption (which drives systemic inflammation and MCAS).

By healing intestinal permeability and supporting mitochondrial efficiency, BPC-157 can meaningfully reduce the fatigue component of long COVID. Standard protocol: 250–500 mcg subcutaneous twice daily for 8–12 weeks.

LL-37 (cathelicidin) has documented antiviral activity against coronaviruses — it disrupts viral envelope lipid membranes and stimulates innate immune (TLR-9, interferon) pathways.

For long COVID patients with evidence of viral reservoir persistence, LL-37 at 1–2 mg subcutaneous 3–5x weekly alongside thymosin alpha-1 provides an immune-mediated clearance approach.